Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.69 |
| ▸ | SLC7A5 | Q01650 | 8/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | XIAP | P98170 | 1/20 | 0.65 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.60 |
| ▸ | NOS3 | P29474 | 3/20 | 0.59 |
| ▸ | NOS1 | P29475 | 3/20 | 0.59 |
| ▸ | NOS2 | P35228 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| M-Fluorophenylalanine SCHEMBL42948 | 1.00 | SLC1A1 (0.69) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL42949 | 1.00 | SLC1A1 (0.69) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL288728 | 1.00 | SLC1A1 (0.69) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL29580111 | 1.00 | SLC1A1 (0.69) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL27547062 | 0.98 | SLC1A1 (0.68) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL21057063 | 0.98 | SLC1A1 (0.68) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL21057062 | 0.98 | SLC1A1 (0.68) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31369781 | 0.91 | GRIA2 (0.71) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| M-Fluorophenylalanine SCHEMBL366761 | 0.89 | PTPN1 (0.57) | SLC1A1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL2314258 | 0.87 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094701-A | TLR3 binding bicyclic peptide ligands | — | 2026-05-26 | — | — | CN | claimed |
| EP-4745151-A1 | FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| US-12521455-B2 | Kisspeptin receptor (KISS1R) targeted therapeutics and uses thereof | RADIONETICS ONCOLOGY, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | claimed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-10-09 | — | — | US | claimed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250186541-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-06-12 | — | — | US | claimed |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | claimed |
| US-20250154198-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2025-05-15 | — | — | US | claimed |
| EP-4077349-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | BicycleTX Limited (GB) | 2022-10-26 | — | — | EP | claimed |
| WO-2022195287-A9 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-10-20 | — | — | WO | claimed |
| US-20220296726-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-09-22 | — | — | US | claimed |
| WO-2022195287-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-09-22 | — | — | WO | claimed |
| WO-2022177744-A1 | GIP/GLP1 DUAL AGONIST THERAPEUTIC METHODS | ELI LILLY AND COMPANY (US) | 2022-08-25 | — | — | WO | claimed |
| CN-114787177-A | IL-17 specific bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2022-07-22 | — | — | CN | claimed |
| WO-2022148968-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2022-07-14 | — | — | WO | claimed |
| US-20220213145-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LIMITED (GB) | 2022-07-07 | — | — | US | claimed |
| EP-3661948-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LTD (GB) | 2022-06-01 | — | — | EP | claimed |
| EP-3989997-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS | Washington University (US) | 2022-05-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | SLC1A1 3185/4885SLC7A5 2440/4885PTGS1 2282/4885 |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | SLC1A1 3965/4885SLC7A5 1732/4885PTGS1 1594/4885 |
| US-20250186541-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDLIM5 | SLC1A1 2102/4885SLC7A5 1303/4885PTGS1 4817/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | SLC1A1 1537/4885SLC7A5 843/4885PTGS1 4251/4885 |
| US-20250312499-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | KISS1R, GNRHR, PROKR1 | SLC1A1 708/4885SLC7A5 2164/4885PTGS1 3753/4885 |
| US-20220296726-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | APP, TIMCC, ADM2 | SLC1A1 1861/4885SLC7A5 2481/4885PTGS1 3076/4885 |
| US-20220213145-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | CD2BP2, CD40, SDC1 | SLC1A1 1939/4885SLC7A5 1031/4885PTGS1 4353/4885 |
| US-20250154198-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL33 | SLC1A1 2969/4885SLC7A5 3106/4885PTGS1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.